



Report #:  
IF-824-QSA-TR006-2026-135-08

Page 1 of 2

Title:

Certificate of Analysis (CoA)

Date:

Date Tested:

Customer:

Testing material:

Lot Number:

BT Sample ID:

Labeled Peptide

Content/Potency:

Storage:

Visual Description:

Labeled as:

Manufacturer:

Testing Purpose:

3/7/2026

3/5/2026

Finnrick

Tirzepatide [Expedited]

VKJPYCP

005000039112874

40 mg


R.T.

small clear vial: white sample, white label, silver crimp, red plastic cap.

Tirzepatide [Expedited]

n/a

FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins.



| Test                                         | Method        | Specification                                                                  | Result                                                                                                       |
|----------------------------------------------|---------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| General Appearance                           | USP<br><630>  | white powder                                                                   | white powder                                                                                                 |
| Mass                                         | USP<br><41>   | As recorded                                                                    | 111.2 mg                                                                                                     |
| FTIR Identification and Composition Analysis | USP<br><197A> | Sample spectrum should confirm the content of peptide via characteristic bands | FTIR sample spectrum confirms the presence of Tirzepatide [Expedited] with addition of excipient(s)/fillers. |
| HPLC Purity of Peptide Assay                 | USP<br><621>  | Specifications: ≥ 98 %                                                         | 99.7 %                                                                                                       |
| HPLC Potency Assay                           | USP<br><621>  | Specifications: 90 – 110% of 40 mg                                             | 42 mg (105.1 %)                                                                                              |
| Peptide-to-Excipients Ratio                  | USP<br><1151> | Recommended ratios of (1:2) to (1:10) for (peptide: excipients)                | 42 : 69.2 mg (1:1.6)                                                                                         |

The results of the CoA relate only to the item(s) tested and applied to the sample as received.

Andrea Castro, AS  
Scientist-I  
BTLabs

Verna Zheng, AS  
Scientist-I  
BTLabs

5730 Corporate Way | Suite 220 | West Palm Beach, FL 33407  
Phone: (561) 625-0133  
E-mail: [info@btlabtesting.com](mailto:info@btlabtesting.com) | Website: <https://btlabtesting.com>



Report #:


IF-824-QSA-TR006-2026-135-08

Page 2 of 2


Title:

Certificate of Analysis (CoA)

FTIR ID and Composition Analysis: Tirzepatide [Expedited] Lot VKJPYCP



HPLC Purity and Potency Assay @ 280 nm: Tirzepatide [Expedited] Lot VKJPYCP



| Tirzepatide [Expedited] Lot VKJPYCP @ 280 nm |                      |              |
|----------------------------------------------|----------------------|--------------|
| Peak #:                                      | Retention Time (min) | Area (mAU*s) |
| 1                                            | 7.531                | 5895.3       |

5730 Corporate Way | Suite 220 | West Palm Beach, FL 33407  
Phone: (561) 625-0133  
E-mail: [info@btlabtesting.com](mailto:info@btlabtesting.com) | Website: <https://btlabtesting.com>